MYO1E

Across TCGA pan-cancer cohorts, MYO1E mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MYO1E data layer compared with 22 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MYO1E mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MYO1E expression acts as an unfavorable survival marker, although some lineages such as COAD and HNSC show a favorable association.

CCRCC, COAD, and HNSC are the cancer types where MYO1E mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	IV	0.123	0.785	.009	28	view →
COAD	DFS	Median	All	1.000	0.894	.032	24	view →
HNSC	DFS	Tertile	II,III,IV	0.985	0.870	.024	14	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	13	view →
LSCC	OS	Tertile	All	0.804	0.932	.037	4	view →
UCEC	DFS	Quartile	II,III,IV	0.768	0.343	.045	4	view →
LUAD	DFS	Tertile	II,III,IV	0.828	1.000	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MYO1E–CCRCC (OS)

Open the CCRCC breakdown →